Multidose general toxicology studies

Toxicological Testing Handbook: Principles, Applications and Data Interpretation

Volumn , Issue , 2016, Pages 149-184

  Keller, Kit A ^a   Banks, Christopher ^b  

^a Toxicology Consultant ^*  (United States)

^b CTBR Bio Research Inc ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123327147     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (81)

1. Food and Drug Administration. International conference on harmonization: guidance on preclinical safety evaluation of biotechnology-derived pharmaceuticals. Fed Regist 1997; 62:61515.
2. Serabian MA, Pilaro AM. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. Toxicol Pathol 1999; 27:27.
3. Pilaro AM, Serbian MA. Preclinical development strategies for novel gene therapeutic products. Toxicol Pathol 1999; 27:4.
4. Keenan KP. The uncontrolled variable in risk assessment: ad libitum overfed rodents-fat, facts and fiction. Toxicol Pathol 1996; 24:376.
5. Allaben WT, Hart RW. Nutrition and toxicity modulation: the impact of animal body weight on study outcome. Int J Toxicol 1998; 17:1.
6. Kuiper MH, Boeve T, Jansen MW, Roelofs-van J, Thuring JWGM, Wijnands MVW. Ophthalmologic examination in systemic toxicity studies: an overview. Lab Anim 1996; 31:177.
7. Kurata M, Horii I. Blood coagulation test in toxicological studies-review of methods and their significance for drug safety assessment. J Toxicol Sci 2004; 29:13.
8. Heywood R. Target organ toxicity. Toxicol Lett 1981; 8:349.
9. Long GG, Symanowski JT, Roback K. Precision in data acquisition and reporting of organ weights in rats and mice. Toxicol Pathol 1998; 26:316.
10. Carr GJ, Maurer JK. Invited commentary. Precision of organ and body weight data: additional perspective. Toxicol Pathol 1998; 26:321.
11. Roberts R, Cain K, Coyle B, Freathy C, Leonard JF, Gautier JC. Early drug safety evaluation: biomarkers, signatures, and fingerprints. Drug Metab Rev 2003; 35:269.
12. Luft J, Bode G. Integration of safety pharmacology endpoints into toxicology studies. Fundam Clin Pharmacol 2002; 16:91.
13. Marcusson-Stahl M, Cererbrant K. A flow-cytometric NK-cytotoxicity assay adapted for use in rat repeated dose toxicity studies. Toxciology 2003; 193:269.
14. Lewis RW, Billington R, Debryune E, Gamer A, Lang B, Carpanini F. Recognition of adverse and nonadverse effects in toxicity studies. Toxicol Pathol 2002; 30:66.
15. Williams GM, Iatropoulos MJ. Distinguishing adverse from non-adverse effects in drug development. Toxicol Pathol 2002; 30:41.
16. Hamlin R. Extracting "more" from cardio pulmonary studies on beagle dogs. In: Gilman MR, ed. The Canine as a Biomedical Model. Bethesda, MD: American College of Toxicology and LRE, 1985:9.
17. Doherty JD, Cobbe SM. Electrophysiological changes in animal model of chronic cardiac failure. Cardiovas Res 1990; 24:309.
18. Hammond TG, Carlsson L, Davis AS, et al. Methods of collecting and evaluating non-clinical electrophysiology data in the pharmaceutical industry: results of an international survey. Cardiovasc Res 2001; 49:741.
19. Caisey JD, King DJ. Clinical chemistry values for some common laboratory animals. Clin Chem 1980; 26:1877.
20. Loeb WF, Quimby FW. The Clinical Chemistry of Laboratory Animals. New York: Pergamon Press, 1989.
21. Matsuzawa T, Nomura M, Unno T. Clinical pathology reference ranges of laboratory animals. J Vet Med Sci 1993; 55:351.
22. Nachbaur J, Clarke MR, Provost JP, Dancia JL. Variations of sodium, potassium and chloride plasma levels in the rat with age and sex. Lab Anim Sci 1977; 27:972.
23. Uchiyama T, Tokoi K, Deki T. Successive changes in the blood composition of the experimental normal beagle dogs accompanied with age. Exp Anim 1985; 34:367.
24. Matsuzawa T, Sakazume S. Effect of fasting on haematology and clinical chemistry values in the rat and dog. Comp Haematol Int 1994; 4:152.
25. Neptun DA, Smith CN, Irons R. Effect of sampling site and collection method on variations in baseline clinical pathology parameters in fischer 344 rats. Fund Appl Toxicol 1985; 5:1180.
26. Walter GL. Effects of carbon dioxide inhalation on hematology, coagulation, and serum clinical chemistry values in rats. Toxicol Pathol 1999; 27:217.
27. Evans GO. Animal Clinical Chemistry: A Primer for Toxicologists. London: Taylor and Francis, 1996.
28. Beynon AC. Animal models for cholesterol metabolism. In: Beynon AC, Solleveld HA, eds. Biosciences. Dordrecht: Martinus Nijoff, 1988:279.
29. Ramaswamy M, Wallace TL, Cossum PA, Wasan KM. Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog, and rat plasma. Antimicrob Agents Chemother 1999; 43:1424.
30. Stonard. Assessment of renal function and damage in animal species. A review of the current approach of the academic, governmental and industrial institutions represented by the animal clinical chemistry association. J Appl Toxicol 1990; 10:267.
31. Jung K, Mattenheimer H, Burchardt U. Urinary Enzymes in Clinical and Experimental Medicine. Berlin: Springer, 1992.
32. Scharer K. The effect of chronic underfeeding on organ weights of rats. Toxicology 1977; 7:45.
33. Farrow MG. Unique aspects of GLP pathology. J Am Coll Toxicol 1987; 6:389.
34. Roe FJC. Toxicity testing: some principles and some pitfalls in histopathologic evaluation. Human Toxicol 1988; 7:405.
35. Ruben Z, Wagner BM. Correlations between morphologic and functional changes induced by xenobiotics: is every induced change a sign of toxicity. Toxicol Appl Pharmacol 1989; 97:4.
36. Haschek WM, Rouseaux CG. Handbook of Toxicologic Pathology. New York: Academic Press, 1991.
37. Davidson IWF, Parker JC, Beliles RP. Biological basis for extrapolating across mammalian species. Reg Toxicol Pharmacol 1986; 6:211.
38. Ruelius HW. Extrapolation from animals to man: predictions, pitfalls and perspectives. Xenobiotic 1987; 17:255.
39. Brown SL, Brent SM, Gough M, et al. Review of interspecies risk comparisons. Reg Toxicol Pharmacol 1988; 8:191.
40. Gephart LA, Salminen WF, Nicolich MJ, Pelekis M. Evaluation of subchronic toxicity data using the benchmark dose approach. Regul Toxicol Pharmacol 2001; 33:37.
41. Kramer HJ, Van Der Ham WA, Slob W, Pieters MN. Conversion factors estimating indicative chronic no-observed-adverse-effect levels from short-term toxicity data. Regul Toxicol Pharmacol 1996; 23:249.
42. Atherley G. A critical review of time-weighted average as an index of exposure and dose of its key elements. Am Ind Hyg Assoc J 1985; 46:481.
43. Sharratt M. Assessing risk from data on other exposure routes. Regul Toxicol Pharmacol 1988; 8:399.
44. Lu FC. A review of the acceptable daily intakes of pesticides assessed by WHO. Regul Toxicol Pharmacol 1995; 21:352.
45. Fairhurst S. Hazard and risk assessment of industrial chemicals in the occupational context in Europe: some current issues. Food Chem Toxicol 2003; 41:1453.
46. Calabrese EJ. Principles of Animal Extrapolation. New York: Wiley-Interscience, 1983:538.
47. Hattis D, Baird S, Goble R. A straw man proposal for a quantitative definition of the RfD. Drug Chem Toxicol 2002; 25:403.
48. Plaa GL, Hewitt WR. Toxicology of the Liver. New York: Raven Press, 1982.
49. Woodman DD. Assessment of hepatic function and damage in animal species. J Appl Toxicol 1988; 8:249.
50. Amacher DE. A toxicologist's guide to biomarkers of hepatic response. Human Exp Toxicol 2002; 21:253.
51. Waterfield CJ, Turton JA, Scales MDC, Timbrell JA. Investigations into the effects of various hepatotoxic compounds on urinary and liver taurine levels in rats. Arch Toxciol 1993; 67:244.
52. Waterfield CJ, Turton JA, Scales MDC, Timbrell JA. Effects of various non-hepatotoxic compounds on urinary and liver taurine levels in rats. Arch Toxicol 1993; 67:538.
53. O'Brien PJ, Slaughter MR, Polley SR, Kramer K. Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Lab Anim 2002; 36:313.
54. Willimas GM, Iatropoulos MJ. Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity. Toxicol Pathol 2002; 30:41.
55. Groneberg DA, Grosse-Siestrup C, Fischer A. In vitro models to study hepatotoxicity. Toxicol Pathol 2002; 30:394.
56. Grosse-Siestrup C, Pfeffere J, Unger V, et al. Isolated hemoperfused slaughterhouse livers as a valid model to study hepatotoxicity. Toxicol Pathol 2002; 30:749.
57. Hook JB, Goldstein RS. Toxicology of the Kidney. New York: Raven Press, 1993.
58. Commandeur JNM, Vermeulen NPE. Molecular and biochemical mechanisms of chemically induced nephrotoxicity: a review. Chem Res Toxicol 1990; 3:171.
59. Mudge GH. Comparative pharmacology of the kidney: implications for drug-induced renal failure. In: Bach PH et al. ed. Nephrotoxicity: Assessment and Pathogenesis. Chichester: Wiley, 1982:504.
60. Bovee KC. Renal function and laboratory evaluation. Toxicol Pathol 1986; 14:26.
61. Hottendorf GH. Functional-morphologic correlations in assessing renal toxicity. Toxicol Pathol 1986; 14:123.
62. Fent K, Mayer E, Zbinden G. Nephrotoxicity screening in rats: a validation study. Arch Toxicol 1988; 61:349.
63. Trevisan A, Giralso M, Borella M, Bottegal S, Fabrello A. Tubular segment-specific biomarkers of nephrotoxicity in the rat. Toxicol Lett 2001; 124:113.
64. Swenberg JA. α2u-Globulin nephropathy: review of the cellular and molecular mechanisms involved and their implications for human risk assessment. Environ Health Perspect 1993;101:39.
65. Acosta D, Jr. Cardiovascular Toxicology. New York: Raven Press, 1992.
66. Louden C, Morgan DG. Pathology and pathophysiology of drug-induced arterial injury in laboratory animals and its implications on the evaluation of novel chemical entities for human clinical trials. Pharmacol Toxicol 2001; 89:158.
67. Irons RD. Toxicology of the Blood and Bone Marrow. New York: Raven Press, 1985.
68. Rosman R, Hanninen O. Gastrointestinal Toxicology. Amsterdam: Elsevier, 1986.
69. Hayes AW. Toxicology of the Eye, Ear, and Other Special Senses. New York: Raven Press, 1985.
70. Balwin HA, McDonald TO, Beasley CH. Slit-lamp examination of experimental animal eyes. Grading scales and photographic evaluation of induced pathological conditions. J Soc Cosmet Chem 1973; 24:181.
71. Hobson DW. Dermal and Ocular Toxicology Fundamentals and Methods. Boca Raton, Florida: CRC Press, 1991.
72. Ribelin ES, Mosley MT. Effects of drugs and chemicals upon the structure of the adrenal gland. Fund Appl Toxicol 1984; 4:105.
73. Colby HD. Adrenal gland toxicity: chemically induced dysfunction. J Am Coll Toxicol 1988; 7:45.
74. Capen CC. Correlation of mechanistic data and histopathology in the evaluation of selected toxic endpoints of the endocrine system. Toxicol Lett 1998; 102-103:405.
75. Boyd EJS, Rinderknecht H, Wormsley KG. Laboratory tests in the diagnosis of the chronic pancreatic diseases. Part 4. Tests involving measurements of pancreatic enzymes in body fluid. Int J Pancreatol 1988; 3:1.
76. Wilmink T, Frick TW. Drug-induced pancreatitis. Drug Saf 1996; 14:406.
77. Nuwaysir EF, Bittner M, Trent J, Barrett JC, Afshari CA. Microarray and toxicology: the advent of toxicogenomics. Mol Carcinogen 1999; 24:153.
78. Cockerell GL, McKim JM, Vonderfetch SL. Strategic importance of research support through pathology. Toxicol Pathol 2002; 30:4.
79. Man WJ, White IR, Bryant D, et al. Protein expression analysis of drug-mediated hepatoxicity in the Sprague-Dawley rat. Proteomics 2002; 2:1577.
80. Thome-Kromer B, Bonk I, Klatt M, et al. Toward the identification of liver toxicity markers: a proteome study in human cell culture and rats. Proteomics 2003; 3:1835.
81. Amin RP, Vickers AE, Sistare F, et al. Identification of putative gene based markers of renal toxicity. Environ Health Perspect 2004; 112:465.